Progressive Multifocal Leukoencephalopathy Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

DelveInsight has launched a new report on "Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast-2030." 

 

DelveInsight's "Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Progressive Multifocal Leukoencephalopathy , historical and forecasted epidemiology as well as the Progressive Multifocal Leukoencephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the Facts:

·         Each year, it is estimated that 4000 people develop PML in the United States and Europe combined.

·         PML occurs in approximately one in 200,000 people.

·         PML is associated with both HIV-1 and HIV-2.

·         HIV infection accounts for almost 85% of the total cases, and its prevalence in this population is around 4-5%

 

Scope of the Report:

  • The report covers the descriptive overview of Progressive Multifocal Leukoencephalopathy , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Progressive Multifocal Leukoencephalopathy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Progressive Multifocal Leukoencephalopathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Progressive Multifocal Leukoencephalopathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Progressive Multifocal Leukoencephalopathy market

 

Request For Free Sample Report: https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-market

 

“PML groups did not differ in terms of age or gender.”

Progressive multifocal leukoencephalopathy is a disease that attacks part of your brain. It happens if your body can't fight off disease the way it should.

It damages your brain's white matter -- cells that make a substance called myelin. This protects your nerves, and losing it can make it harder for you to move, think, and feel sensations.

PML is a very serious illness that can be fatal.

It's caused by a virus called the JC virus. Most adults carry it, and it usually doesn't cause any health problems. But it can if you have a weak immune system -- if your body's natural defenses against illness aren't working right.

Symptoms

The first signs of PML can be different from person to person, depending on the nerves that are damaged first. But they often include:

  • Clumsiness or loss of coordination
  • Difficulty walking
  • Facial drooping
  • Loss of vision
  • Personality changes
  • Trouble speaking
  • Weak muscles

 

Request For Free Sample Report: https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-market

 

Some of the Companies Involved are:

·         Excision BioTherapeutics Inc

·         Neuway Pharma GmbH

·         Humabs BioMed SA

·         Neurimmune Holding AG

·         Pomona Ricerca SRL

·         And Many Others

 

Some of the Drugs Covered are:

·         EBT-103

·         IKT-01427

·         Imatinib Mesylate

·         NI-307

·         And Many Others

 

Request For Free Sample Report: https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-market

 

Table Of Content:

1. Key Insights

2. Executive Summary of Progressive Multifocal Leukoencephalopathy

3. Competitive Intelligence Analysis for Progressive Multifocal Leukoencephalopathy

4. Progressive Multifocal Leukoencephalopathy : Market Overview at a Glance

4.1. Progressive Multifocal Leukoencephalopathy Total Market Share (%) Distribution in 2017

4.2. Progressive Multifocal Leukoencephalopathy Total Market Share (%) Distribution in 2030

5. Progressive Multifocal Leukoencephalopathy : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Progressive Multifocal Leukoencephalopathy Risk Factors 

5.5. Progressive Multifocal Leukoencephalopathy Diagnosis 

6. Patient Journey

7. Progressive Multifocal Leukoencephalopathy Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Progressive Multifocal Leukoencephalopathy Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Progressive Multifocal Leukoencephalopathy Treatment and Management

8.2. Progressive Multifocal Leukoencephalopathy Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Progressive Multifocal Leukoencephalopathy Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Progressive Multifocal Leukoencephalopathy Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Progressive Multifocal Leukoencephalopathy Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Progressive Multifocal Leukoencephalopathy : Seven Major Market Analysis

13.1. Key Findings

13.2. Progressive Multifocal Leukoencephalopathy Market Size in 7MM

13.3. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Progressive Multifocal Leukoencephalopathy Market Size

15.1.1. Progressive Multifocal Leukoencephalopathy Total Market Size in the United States

15.1.2. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in the United States

15.2. EU-5 countries: Progressive Multifocal Leukoencephalopathy Market Size and Outlook

15.3. Germany Progressive Multifocal Leukoencephalopathy Market Size

15.3.1. Progressive Multifocal Leukoencephalopathy Total Market Size in Germany

15.3.2. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in Germany

15.4. France Progressive Multifocal Leukoencephalopathy Market Size

15.4.1. Progressive Multifocal Leukoencephalopathy Total Market Size in France

15.4.2. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in France

15.5. Italy Progressive Multifocal Leukoencephalopathy Market Size

15.5.1. Progressive Multifocal Leukoencephalopathy Total Market Size in Italy

15.5.2. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in Italy

15.6. Spain Progressive Multifocal Leukoencephalopathy Market Size

15.6.1. Progressive Multifocal Leukoencephalopathy Total Market Size in Spain

15.6.2. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in Spain

15.7. United Kingdom Progressive Multifocal Leukoencephalopathy Market Size

15.7.1. Progressive Multifocal Leukoencephalopathy Total Market Size in the United Kingdom

15.7.2. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in the United Kingdom

15.8. Japan Progressive Multifocal Leukoencephalopathy Market Outlook

15.8.1. Japan Market Size

15.8.2. Progressive Multifocal Leukoencephalopathy Total Market Size in Japan

15.8.3. Progressive Multifocal Leukoencephalopathy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Progressive Multifocal Leukoencephalopathy

17. KOL Views

18. Progressive Multifocal Leukoencephalopathy Market Drivers

19. Progressive Multifocal Leukoencephalopathy Market Barriers

20. Appendix

20.1. Bibliography

20.2. Progressive Multifocal Leukoencephalopathy Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-market

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for

Browse through our vast repository from here.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

 


Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more

Vernal Keratoconjunctivitis Market

(Albany, US) DelveInsight’s “ Vernal Keratoconjunctivitis Market  Insights, Epidemiology, and Market Forecast-2030 ” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the key facts of the  Vernal Keratoconjunctivitis Market The increasing population and rising prevalence of Vernal Keratoconjunctivitis generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by Vernal Keratoconjunctivitis in the global market. China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017. The total diagnosed prevalent population of Vernal Keratoconjunctivitis was 2,943,057 in the global market.   Request for Sample Report: https://www.delveinsight.com/report-store...
Read more